Rampart Securities

Rampart Bioscience is a biotechnology company focused on developing a new class of non-viral gene medicines designed to provide durable and redosable treatments for genetic diseases. The company utilizes its proprietary HALO (Highly Adaptive Long-term Organ-specific) platform to create DNA-based therapies that aim to overcome the limitations of traditional viral vectors, such as immunogenicity and limited payload capacity. Its lead program, RAMP-001, is being developed for the treatment of hypophosphatasia, a rare and potentially fatal genetic disorder characterized by defective bone mineralization. By leveraging a non-viral approach, Rampart aims to deliver therapeutic genes safely and effectively while allowing for repeat dosing if necessary. Headquartered in San Diego, the company was launched in 2023 with an $85 million Series A financing led by Forbion. The leadership team includes industry veterans with extensive experience in the development of genetic medicines and rare disease therapies.